NEW YORK, Feb. 17, 2012 /PRNewswire/ -- The arsenal of prostate cancer treatments  for men with advanced prostate cancer  may soon be strengthened as the FDA prioritizes the review of both Ra-223 and MDV3100 for treating metastatic castration-resistant prostate cancer (CRPC). Based on positive, independent research of each drug, better survival rates and improved bone health for patients with late-stage prostate cancer may be within reach.
(Photo: http://photos.prnewswire.com/prnh/20120217/NY55303  )
Dr. David Samadi is Vice Chairman, Department of Urology, and Chief of Robotics and Minimally Invasive Surgery at The Mount Sinai Medical Center and a leading robotic surgery expert  and PSA test  advocate. He commended the efforts behind these advancements by saying, "I'm encouraged to see advanced prostate cancer treatment drugs  that may not only extend life, but do so with improved patient health. That's the key – prolonging life with quality." Previous drug therapies, such as Provenge or Zytiga, have proven to extend survival rates, though do not offer additional benefits to the patient.
The drug Radium-223 chloride, also known as Ra-223 or Alpharadin, delivers radiation to the bone and the prostate cancer tumor. In trial, the drug improved patient survival by an average of three months. In addition, patients undergoing Ra-223 drug therapy experienced delayed bone damage or need for surgery or radiation by more than five months.
Medivation, or MDV3100, is an androgen inhibitor that prevents prostate cancer tumor growth by binding with cancer cell r